Meanwhile, investors await key clinical data.

Tiragolumab failed the Skyscraper-14 and 03 studies, Roche quietly reveals.

But BeOne canned its alcestobart deal in May.

Biopharma's interest in CDH17 and CDH6 continues, courtesy of Lepu and Qilu.

The company claims a 69% response rate with iSCIB1+, but only in a “target population”.

There are questions about vuso-vec’s supporting and confirmatory trials.